Figure 5.
Anti-HPV16 IgG titers (Y-axis) in different weeks (X-axis) of 5 groups: vaccine in solution and in MPs using Formulation 1 (containing 60% CPD, 15% HPMCAS, 15% EC)—transdermal route, vaccine in solution and in MPs using Formulation 2 (contained 20% CPD, 34% CPD, 34% EC)—transdermal route, and the positive control group (Gardasil)—intramuscular route. The vertical lines show geometric mean titers (log 10) and 95% confidence intervals.